Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

New Data Highlight Innovative Ways to Assess Patients with Early Alzheimer's Disease and Later Stage Alzheimer's Disease Dementia

Posted on: 30 Oct 17

WOODCLIFF LAKE, N.J., Oct. 30, 2017 /PRNewswire/ -- Eisai Inc. announced today the presentation of three posters during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting, highlighting data on innovative ways to screen for cognitive impairment and sleep disorders associated with mild to moderate stages of AD dementia.   

"Our poster on sleep-wake patterns includes baseline data derived by wrist actigraphy from a Phase 2 study of a novel treatment for Irregular Sleep-Wake Rhythm Disorder (ISWRD) in Alzheimer's dementia patients," said Lynn Kramer, M.D., Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "Through new and continued research, we aim to further understand how treating ISWRD can impact the quality of life for patients and their families."

Two other posters presented at the meeting will look the use of the International Shopping List Test (ISLT) as an objective cognitive assessment to select individuals with early Alzheimer's disease in clinical trials, including Eisai's Phase 3 trial of elenbecestat (E2609).                                   

For more information:

Editor's Details

Mike Wood

Last updated on: 30/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.